Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Recruiting 3Completed 3Active not recruiting 3Terminated 1Enrolling by invitation 1Available 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

pembrolizumab 382Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 208Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 148atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102venetoclax 98fludarabine 97Radiosurgery 94Capecitabine 94Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × brexucabtagene autoleucel × 1 year × Clear all
NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06253663 2025-12-16

JKART-1

Gilead Sciences

Phase 2 Active not recruiting
25 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡